Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amanda Samuels

Nurse Practitioner Elizabethtown, KY Nurse Practitioner

NPI 1073744702 CMS profile 11096867

100 Helmwood Plaza Dr, Elizabethtown, KY 42701

Open in the dashboard

General payments

$6,124

396 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Samuels of Elizabethtown, KY is reported in the CMS Open Payments database as having received $6,124 across 396 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,167 68
2024 General $1,145 75
2023 General $1,278 92
2022 General $948 82
2021 General $1,586 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Samuels
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Amanda Samuels were reported at $1,167. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Amanda Samuels Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,586 $135 $40–$426 $132
2022 $948 $152 $48–$470 $149
2023 $1,278 $166 $54–$529 $160
2024 $1,145 $173 $55–$556 $164
2025 $1,167 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Pfizer Inc. $727 52 payments
  2. Biohaven Pharmaceuticals, Inc. $700 23 payments
  3. AbbVie, Inc. $658 53 payments
  4. Novo Nordisk Inc $653 57 payments
  5. GlaxoSmithKline, LLC. $344 26 payments
  6. Amgen Inc. $318 21 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $303 28 payments
  8. AstraZeneca Pharmaceuticals LP $288 12 payments
  9. Otsuka America Pharmaceutical, Inc. $251 12 payments
  10. Lilly USA, LLC $244 15 payments
  11. Other $1,637 97 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,124 396 payments
Products named General payments · program years 2021–2025
  1. NURTEC ODT Primary Care $1,003 51 payments
  2. ZAVZPRET $419 33 payments
  3. UBRELVY $376 23 payments
  4. NURTEC ODT Pain $374 39 payments
  5. QULIPTA $259 18 payments
  6. REXULTI $251 12 payments
  7. TRELEGY ELLIPTA $242 19 payments
  8. Wegovy $218 19 payments
  9. VRAYLAR $184 20 payments
  10. BREZTRI $176 4 payments
  11. Other $3,946 264 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 130 drugs

Part D claims

5,725

Median for Nurse Practitioner: 389

Drug cost

$605,190

Median for Nurse Practitioner: $21,885

Branded share of claims

23%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 91 $84,355
Januvia Sitagliptin Phosphate Brand 42 $55,916
Ozempic Semaglutide Brand 52 $49,266
Eliquis Apixaban Brand 53 $48,245
Janumet Xr Sitagliptin Phos/Metformin Hcl Brand 36 $46,861
Mounjaro Tirzepatide Brand 32 $38,382
Repatha Sureclick Evolocumab Brand 46 $31,754
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 27 $28,024
Trulicity Dulaglutide Brand 20 $27,690
Myrbetriq Mirabegron Brand 22 $22,924

The 10 drugs with the highest cost, of 130 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$63,867

Of which drugs: $10,737

Medicare patients

225

Average age 71

Services billed

1,857

135 women, 90 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 36%
COPD 22%
Ischemic heart disease 21%
Depression 16%
Cancer 15%
Chronic kidney disease 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 62 63 $5,023
Pcv20 vaccine im 90677 Office 17 17 $4,901
Injection, methylprednisolone acetate, 1 mg J1010 Office 14 721 $65

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZAVZPRET
  • PFIZER INC. $178
$178 — —
UBRELVY
  • AbbVie, Inc. $65
$65 — —
NURTEC ODT
  • PFIZER INC. $65
$65 12 —
ZEPBOUND
  • Lilly USA, LLC $57
$57 — —
QULIPTA
  • AbbVie, Inc. $56
$56 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

396 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record